Search Results
Results found for "Timo De Groof"
- Fluorescence Polarization in GPCR Research
techniques used in HTS, among them Fluorescence Polarization (FP) is especially useful since it allows real time Not time-sensitive Once equilibrium has been reached the assay remains stable for extended periods (at L, González A, Gioé-Gallo C, Mallo-Abreu A, Brea J, Loza MI, García-Rey A, García-Mera X, Gutiérrez-de-Terán
- GPCR Collaboration: From Models to Medicine
But Carlsson doesn’t try to do everything under one roof. Over time, that transparency has built enduring partnerships , including one of Carlsson’s earliest with In practice, this approach saves companies time, resources, and credibility with investors. Carlsson’s lab is a proof point : collaboration is not just a cultural preference.
- Are You Guessing or Forecasting? Master GPCR Pharmacologic Models Before It’s Too Late
Hi GPCR Fanatics, This week’s insights will help you avoid wasted time, poor forecasts, and stalled costly errors: Master vital models to confidently forecast outcomes, before it’s too late. ✅ Future-proof
- When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue
a patch of fluorescence — the entire pancreatic islet , 100–200 microns across, lighting up in real time It wasn’t just successful GPCR imaging — it was proof that receptors could be seen as they truly exist Not one receptor at a time. Not one color. Not one imaging depth. It was the proof of concept.
- Artificial intelligence – faster, smarter, cheaper GPCR drug discovery
notable differences in respect to neural network architecture, complexity, data requirements, training time DL models generally require more computational resources (such as powerful GPUs) and longer training times De novo drug design: AI algorithms can generate new molecules with desired properties, such as binding chemical space, limiting their ability to identify truly novel chemotypes”(Thomas, Smith, O’Boyle, de
- Unlocking the Future of Medicine: Advancements in GPCR Research
This week's highlight includes congrats to Omolade Otun, Chris de Graaf, Cherine Bechara, et al. for Understanding real-time kinetics to predict activity and in vivo target coverage.
- Cholesterol occupies the lipid translocation pathway to block phospholipid scrambling by a GPCR
membrane-embedded opsin indicated that phospholipid headgroups traverse a dynamically revealed hydrophilic groove cholesterol inhibits phospholipid scrambling by occupying the TM6/7 interface and stabilizing the closed groove
- Identification of A2BAR as a potential target in colorectal cancer using novel fluorescent GPCR...
As well, fluorescent ligands were effective at monitoring real-time A2BAR receptor labeling using live-imaging This proof-of-concept study suggests the use of fluorescent ligands for GPCR characterization through
- 📰 GPCR Weekly News, March 6 to 12, 2023
Domain Therapeutics was nominated for the Trophée de l'Innovation Technologique (Technological Innovation
- Beyond Clearance: The Strategic Power of Irreversible Drug Binding
running early-stage programs, recognizing this decoupling early can sharpen dose optimization and de-risk
- Therapeutic validation of an orphan G protein‐coupled receptor
Therefore, matching a ligand to an orphan GPCRs, the process of de-orphanizing, is of great importance
- 📰 GPCR Weekly News, April 10 to 16, 2023
Michel Bouvier received the title of Doctor Honoris Causa from the Université de Montpellier Domain Therapeutics
- Misread the Curve, Misjudge the Drug: Rethinking Antagonism in GPCR Pharmacology
Terry also explores the experimental constraints —like timing and equilibrium—that determine whether Unlock “Competitive Antagonism” Now Only in Terry’s Corner Why Terry’s Corner For discovery-phase teams, time But Terry cautions: “These patterns are consistent with, but not proof of, mechanism.
- Phospholipid Scrambling by G Protein-Coupled Receptors
dynamics simulations of opsin in a lipid membrane reveal conformational transitions that expose a polar groove This groove enables transbilayer lipid movement, conceptualized as the swiping of a credit card (lipid
- 🤯Mind-blowing GPCR Scoops! Discover the Latest Breakthroughs! ⦿ Nov 18 - 24, 2024
GPCR drugmaker Septerna amasses $288M in IPO Surrounded by AI bio giants, tiny startup Nabla Bio makes de
- 📰 GPCR Weekly News, March 27 to April 4, 2023
Adhesion GPCRs Optimized genetic code expansion technology for time-dependent induction of adhesion GPCR-ligand ended 31 December 2022 Addex Raises $5.0 Million in Equity Financing Testing the limits of SMILES-based de
- Competitive vs Non-Competitive GPCR Antagonists: How to Interpret Pharmacology Data with Confidence
Learn how to transform your program from a series of disconnected efforts into a predictable, de-risked
- 📰 GPCR Weekly News, April 8 to 14, 2024
This week's highlight includes congrats to: Tessa de Vries, Graham Ladds, Antoinette MaassenVanDenBrink
- 📢 GPCR Update: August 19-25, 2024 | Thrilling Announcement: New Pharmacology Course Dates & Exclusive Discounts Inside!
Topics cover new cellular assays, real-time kinetics, and unique GPCR behaviors. GPR37-mTOR-S6K1 Signaling GPCRs in Neuroscience Astrocyte Gi-GPCR signaling corrects compulsive-like grooming
- Isoform-and ligand-specific modulation of adhesion GPCR ADGRL3/Latrophilin3 by a synthetic binder
Our work provides proof of concept for the modulation of isoform- and ligand specific aGPCR functions
- Finding needles in haystacks: Omass unveils pipeline aimed at tough-to-drug targets
November 2021 "Nov. 15, 2021 LONDON – There’s not yet proof of the pudding, but Omass Therapeutics Ltd
- Profiling Immune Cell and Platelet Transcriptomes
The researchers conducted a comparative analysis with previous studies, notably the work by Groot-Kormelink
- Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage ...
Venture-like’ capital allocation approach to focus pipeline development through to Phase 1b/2a clinical proof
- A Chemical Biology Toolbox Targeting the Intracellular Binding Site of CCR9: Fluorescent Ligands ...
In a proof-of-principle study, we succeeded in showing that our CCR9-PROTAC is able to reduce CCR9 levels
- How a Failed Med School Dream Sparked a GPCR Biotech Revolution
By making receptor behavior computationally predictable, Ajay and his team are working to reduce the time Ajay's career is proof that in science, the detours are often the real path forward
- G protein-biased GPR3 signaling ameliorates amyloid pathology in a preclinical Alzheimer's disease..
GPR3-mediated G protein and β-arrestin signaling produce discrete and separable effects and provide proof
- The Perils and Guardrails of Modifying Signalling Proteins in Bioassays
Clinical development times for innovative drugs. Seven transmembrane receptors as nature's prototype allosteric protein: de-emphasizing the geography Protein Eng Des Sel. 2016;29(12):583-594. 47. Crilly SE, Ko W, Weinberg ZY,Puthenveedu MA.
- An overview of the compartmentalized GPCR Signaling: Relevance and Implications
Bénard, G., Ramos, A., Reguero, L., Arrabal, S., Elezgarai, I., Gerrikagoitia, I., Suarez, J., Rodríguez De
- 📰 GPCR Weekly News, December 11 to 17, 2023
We'll pause our regular updates during this time and will resume our newsletter in the upcoming year Gastric Inhibitory Polypeptide Receptor (GIPR) Revealed by Trapped-Ion-Mobility Spectrometry Coupled to Time-of-Flight Mass Spectrometry (TIMS-TOF MS) A rapid, tag-free way to purify functional GPCRs tANCHOR fast and cost-effective Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept
- Rescue of Cell Surface Expression and Signaling of Mutant Follicle-Stimulating Hormone Receptors
aid in advancing the understanding of the effects of genetic mutations on GPCR function and provide a proof













